Xencor, Inc. and OCM Life Sciences Portfolio LP, entered into a royalty purchase agreement. Pursuant to the Ultomiris Agreement, OMERS acquired the rights to certain past and potential royalties associated with the existing license relating to Ultomiris® (ravulizumab) in exchange for an upfront payment of $192.5 million. Ultomiris® is a drug being developed and commercialized by Alexion Pharmaceuticals, Inc. (?Alexion?).

Pursuant to the Ultomiris Agreement and subject to the Company?s existing license with Alexion, OMERS has acquired the right to receive: (i) 100% of royalties payable on past and potential sales related to Ultomiris® that occur from July 1, 2023 through December 31, 2025; (ii) up to $35 million annually in royalties on potential sales related to Ultomiris® that occur from January 1, 2026 through December 31, 2028 with any royalties in excess of $35 million reverting to the Company; (iii) up to $12 million annually in royalties on potential sales related to Ultomiris® that occur from and after January 1, 2029, with any royalties in excess of $12 million reverting to the Company; and (iv) $18 million of a certain potential sales based milestone payment pursuant to the existing license with Alexion. Pursuant to the Ultomiris Agreement, OMERS will pay an additional $12 million to the Company if certain potential sales based milestones pertaining to Third Quarter 2023 through Second Quarter 2024 have been reached. The Ultomiris Agreement contains certain covenants, representations and warranties regarding the Company?s rights and obligations with respect to the Company?s existing license with Alexion and customary covenants and representations for a transaction of this nature.

Monjuvi Agreement On November 3, 2023, the Company and OMERS entered into a royalty purchase agreement (the ?Monjuvi Agreement?). Pursuant to the Monjuvi Agreement, OMERS acquired the rights to certain past and potential royalties associated with the existing license relating to Monjuvi®/Minjuvi® (tafasitamab-cxix) in exchange for an upfront payment of $22.5 million. Monjuvi®/Minjuvi® is a drug being developed and commercialized by MorphoSys AG and Incyte Inc. (?MorphoSys?

and ?Incyte?). Pursuant to the Monjuvi Agreement and subject to the Company?s existing license with MorphoSys, OMERS has acquired the right to receive up to $29.25 million in royalties on past and potential sales related to Monjuvi®/Minjuvi® that occur from and after July 1, 2023, with any royalties in excess of $29.25 million reverting to the Company. The Monjuvi Agreement contains certain covenants, representations and warranties regarding the Company?s rights and obligations with respect to the Company?s existing license with MorphoSys and customary covenants and representations for a transaction of this nature.